Assessment of early response to tyrosine kinase inhibitor (erlotinib) in stage IIIB/IV NSCLC by PET/CT

被引：0
|
作者：
Benz, Matthias [1 ]
Walter, Franziska [2 ]
Garon, Edward [3 ]
Phelps, Michael [2 ]
Czernin, Johannes [2 ]
Allen-Auerbach, Martin [1 ]
机构：
[1] Univ Freiburg, Nucl Med, Freiburg, Germany
[2] Univ Calif Los Angeles, Mol & Med Pharmacol, Los Angeles, CA USA
[3] Univ Calif Los Angeles, Med, Los Angeles, CA USA
来源：
JOURNAL OF NUCLEAR MEDICINE | 2011年 / 52卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
426
引用
收藏
页数：1
相关论文
共 50 条
  • [31] 18F-PSMA-1007 PET/CT for response assessment in patients with metastatic renal cell carcinoma undergoing tyrosine kinase or checkpoint inhibitor therapy
    Mittlmeier, L.
    Unterrainer, M.
    Rodler, S.
    Todica, A.
    Albert, N. L.
    Burgard, C.
    Cyran, C. C.
    Kunz, W. G.
    Ricke, J.
    Bartenstein, P.
    Stief, C. G.
    Staehler, M.
    Ilhan, H.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S283 - S284
  • [32] NSCLC at an Early Stage: Tumor Progression in Interscaninterval between diagnostic FDG-PET/CT and Planning PET/CT for SBRT
    Adebahr, S.
    Troost, E.
    Kupferschmid, J.
    Grosu, A-L
    Duncker-Rohr, V
    Mix, M.
    Nestle, U.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2014, 190 : 108 - 109
  • [33] Use of FLT PET Imaging to Assess Tyrosine Kinase Inhibitor (TKI) Treatment Response
    Jeraj, R.
    Vanderhoek, M.
    Simoncic, U.
    Perlman, S.
    Alberti, D.
    Wilding, G.
    Liu, G.
    MEDICAL PHYSICS, 2009, 36 (06)
  • [34] The early response of renal cell carcinoma to tyrosine kinase inhibitors evaluated by FDG PET/CT was not influenced by metastatic organ
    Manabu Kakizoe
    Masahiro Yao
    Ukihide Tateishi
    Ryogo Minamimoto
    Daiki Ueno
    Kazuhiro Namura
    Kazuhide Makiyama
    Narihiko Hayashi
    Futoshi Sano
    Takeshi Kishida
    Kazuki Kobayashi
    Sumio Noguchi
    Ichiro Ikeda
    Yoshiharu Ohgo
    Masataka Taguri
    Satoshi Morita
    Tomio Inoue
    Yoshinobu Kubota
    Noboru Nakaigawa
    BMC Cancer, 14
  • [35] The early response of renal cell carcinoma to tyrosine kinase inhibitors evaluated by FDG PET/CT was not influenced by metastatic organ
    Kakizoe, Manabu
    Yao, Masahiro
    Tateishi, Ukihide
    Minamimoto, Ryogo
    Ueno, Daiki
    Namura, Kazuhiro
    Makiyama, Kazuhide
    Hayashi, Narihiko
    Sano, Futoshi
    Kishida, Takeshi
    Kobayashi, Kazuki
    Noguchi, Sumio
    Ikeda, Ichiro
    Ohgo, Yoshiharu
    Taguri, Masataka
    Morita, Satoshi
    Inoue, Tomio
    Kubota, Yoshinobu
    Nakaigawa, Noboru
    BMC CANCER, 2014, 14
  • [36] PET/CT based imaging biomarkers for response prediction of stage IV NSCLC treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin
    de Long, E. E. C.
    Van Elmpt, W.
    Leijenaar, R. T. H.
    Groen, H.
    Smit, E.
    Boellaard, R.
    Van der Noort, V.
    Troost, E. G. C.
    Lambin, P.
    Dingemans, A-M.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S126 - S127
  • [37] Role of late response evaluation in Non Small Cell Lung Cancer (NSCLC) treated with EGFR Tyrosine Kinase Inhibitor with PET quantitative parameters
    Bhoil, A.
    Mittal, B.
    Singh, N.
    Singh, B.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S307 - S308
  • [38] FDG-PET/CT Based Response Prediction of Stage IV NSCLC Treated with Paclitaxel-Carboplatin-Bevacizumab with or without Nitroglycerin
    De Jong, Evelyn E. C.
    Van Elmpt, Wouter
    Hoekstra, Otto S.
    Groen, Harry J. M.
    Smit, Egbert
    Boellaard, Ronald
    Troost, Esther G. C.
    Lambin, Philippe
    Dingemans, Anne-Marie C.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S654 - S655
  • [39] PSMA PET/CT for tyrosine-kinase inhibitor monitoring in metastatic renal cell carcinoma
    Mittlmeier, L. M.
    Unterrainer, M.
    Todica, A.
    Cyran, C. C.
    Rodler, S.
    Bartenstein, P.
    Stief, C. G.
    Ilhan, H.
    Staehler, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (09) : 2216 - 2217
  • [40] PSMA PET/CT for tyrosine-kinase inhibitor monitoring in metastatic renal cell carcinoma
    L. M. Mittlmeier
    M. Unterrainer
    A. Todica
    C. C. Cyran
    S. Rodler
    P. Bartenstein
    C. G. Stief
    H. Ilhan
    M. Staehler
    European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47 : 2216 - 2217
12345